FTC Warns Pharmaceutical Companies May Face Criminal Action On Improper Patent Listings

The Federal Trade Commission on Thursday (Sep. 14) sent a clear message to pharmaceutical companies: Improper Orange Book patent listings will be investigated, and those found in violation of the law could face criminal action. Alexandra Moss, executive director at the Public Interest Patent Law Institute, told Inside Health Policy that “the policy statement is a huge step in the right direction -- stronger and better than expected.” “It also meaningful that the statement says submitting a false certification...